Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
306,013

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's Breast Cancer Study Meets Co-Primary Endpoint

by Zacks Equity Research

Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

    Celgene's Luspatercept Meets Primary Endpoint in the Study

    by Zacks Equity Research

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.

      Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall

      by Zacks Equity Research

      Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.

        Medicines Company's Inclisiran Studies to Continue Unmodified

        by Zacks Equity Research

        The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.

          Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review

          by Zacks Equity Research

          Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.

            Infinity and Arcus Ink Deal for Two Triple Combo Studies

            by Zacks Equity Research

            : Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.

              Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote

              by Zacks Equity Research

              Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.

                Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

                by Zacks Equity Research

                Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.

                  Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA

                  by Zacks Equity Research

                  Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.

                    Pfizer's Breast Cancer Drug Misses Overall Survival in Study

                    by Zacks Equity Research

                    Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.

                      Merrimack Crashes as Phase II Pancreatic Cancer Study Fails

                      by Zacks Equity Research

                      Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.

                        Novo Nordisk (NVO) Announces Results in Diabetes Studies

                        by Zacks Equity Research

                        Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

                          Anika Reports Top Line Data from CINGAL Study, Shares Slump

                          by Zacks Equity Research

                          Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.

                            Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

                            by Zacks Equity Research

                            Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

                              Alexion (ALXN) Submits Application for ALXN1210 with FDA

                              by Zacks Equity Research

                              Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

                                Roche to Buy Rest of Foundation Medicine for $2.4 billion

                                by Zacks Equity Research

                                Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

                                  4 Undervalued MedTech Stocks to Consider Amid Volatility

                                  by Zacks Equity Research

                                  Amid turbulences of the U.S. market, some value stocks of MedTech industry appear to be lucrative investment options.

                                    Flex Pharma Down on Workforce Reduction, Ends Phase II Study

                                    by Zacks Equity Research

                                    Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.

                                      Sarepta Inks Manufacturing Deal for Gene Therapy Program

                                      by Zacks Equity Research

                                      Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

                                        Here's Why Sarepta is Up More Than 60% So Far This Year

                                        by Zacks Equity Research

                                        Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

                                          BioMarin's Palynziq Gets FDA Approval for Phenylketonuria

                                          by Zacks Equity Research

                                          BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.

                                            INSYS Gets Negative FDA Recommendation for Pain Candidate

                                            by Zacks Equity Research

                                            INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

                                              Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?

                                              by Zacks Equity Research

                                              Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.

                                                Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?

                                                by Zacks Equity Research

                                                Let's put ANI Pharmaceuticals (ANIP) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                                                  Pfizer Hikes Dividend, Announces $10B Share Buyback Plan

                                                  by Zacks Equity Research

                                                  Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.